Drug Trial Radar · NCT00531596
Evaluation of Adhesion and Dermal Tolerability of EMSAM
Last checked: Nov 20, 2026Latest source record: Sep 19, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Apr 2007
Primary completion
Not stated
Study completion Jul 2007
Sponsor
- Lead sponsor
- Somerset PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Examine adhesive and dermal tolerability of EMSAm 6mg/24hr and 12mg/24hr in healthy elderly and non-elderly subjects.
Conditions
- Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24HrDrug
EMSAM 6mg/24HR
EMSAM (Selegiline Transdermal System) 9mg/24HrDrug
EMSAM 9mg/24Hr
EMSAM (Selegiline Transdermal System) 12mg/24hrDrug
EMSAM 12mg/24Hr
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adhesion characteristics and dermal tolerability (irritation) of EMSAM in two populations consisting of non-elderly (18 - 64 years) and elderly (65 years and older) healthy volunteers.Time frame: 21 Days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hill Top Research
Scottsdale, Arizona
Hill Top Research
St. Petersburg, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.